Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 20/20 | 0.69 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.69 |
| ▸ | DRD5 | P21918 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356363 | 0.94 | GALR3 (0.78) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL5356357 | 0.94 | GALR3 (0.78) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL915969 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8452654 | 0.91 | GALR3 (0.69) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL915968 | 0.91 | GALR3 (0.83) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8427817 | 0.91 | GALR3 (0.69) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL5359948 | 0.86 | GALR3 (0.78) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL5359954 | 0.86 | GALR3 (0.78) | GALR3HTR4DRD5ADRA1A | |
| SCHEMBL8250426 | 0.85 | GALR3 (0.48) | GALR3HTR4 | |
| SCHEMBL5356928 | 0.83 | GALR3 (0.81) | GALR3HTR4DRD5ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166635-B2 | 3-imino-2-indolones for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2007-01-23 | — | — | US | disclosed |
| US-7166635-B2 | 3-imino-2-indolones for the treatment of depression and/or anxiety | H. LUNDBECK A/S (DK) | 2007-01-23 | — | — | US | disclosed |
| US-20050148635-A1 | 3-imino-2-indolones for the treatment of depression and/or anxiety | SYNAPTIC PHARMACEUTICAL CORPORATION | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148635-A1 | 3-imino-2-indolones for the treatment of depression and/or anxiety | GALR3, GALR2, GALR1 | GALR3 1/4885HTR4 17/4885DRD5 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.